Search for 'an:"86" and au:Ruilope Urioste, Luis Miguel'

Fixed-Combination Olmesartan/Amlodipine Was Superior to Perindopril + Amlodipine in Reducing Central Systolic Blood Pressure in Hypertensive Patients With Diabetes.

By Ruilope Urioste, Luis Miguel. The journal of clinical hypertension, 2016 . 18(6):528-35. , Formato Vancouver: Ruilope LM; SEVITENSION Study Investigators. Fixed-Combination Olmesartan/Amlodipine Was Superior to Perindopril + Amlodipine in Reducing Central Systolic Blood Pressure in Hypertensive Patients With Diabetes. J Clin Hypertens (Greenwich). 2016 Jun;18(6):528-35.

Place Hold on Fixed-Combination Olmesartan/Amlodipine Was Superior to Perindopril + Amlodipine in Reducing Central Systolic Blood Pressure in Hypertensive Patients With Diabetes.

Continuation of the ESH-CHL-SHOT trial after publication of the SPRINT: rationale for further study on blood pressure targets of antihypertensive treatment after stroke.

By Rodicio Díaz, José Luis | Ruilope Urioste, Luis Miguel. Journal of hypertension, 2016 . 34(3):393-6. , Formato Vancouver: Zanchetti A, Liu L, Mancia G, Parati G, Grassi G, Stramba Badiale M et al; ESH-CHL-SHOT trial investigators. Continuation of the ESH-CHL-SHOT trial after publication of the SPRINT: rationale for further study on blood pressure targets of antihypertensive treatment after stroke. J Hypertens. 2016 Mar;34(3):393-6.

Place Hold on Continuation of the ESH-CHL-SHOT trial after publication of the SPRINT: rationale for further study on blood pressure targets of antihypertensive treatment after stroke.

Estudio del riesgo cardiovascular en pacientes con bloqueo del sistema renina-angiotensina a través del proteoma de las vesículas extracelulares circulantes.

By Ruiz Hurtado, Gema | Segura de la Morena, Julián | Ruilope Urioste, Luis Miguel. Hipertensión y riesgo vascular, 2016 . 33(1):21-7. , Formato Vancouver: De la Cuesta F, Baldán Martín M, Mourino Álvarez L, Sastre Oliva T, Álvarez Llamas G, González Calero L et al. Estudio del riesgo cardiovascular en pacientes con bloqueo del sistema renina-angiotensina a través del proteoma de las vesículas extracelulares circulantes. Hipertens Riesgo Vasc. 2016 Jan-Mar;33(1):21-7.

Place Hold on Estudio del riesgo cardiovascular en pacientes con bloqueo del sistema renina-angiotensina a través del proteoma de las vesículas extracelulares circulantes.

Biomarkers of renal injury and function: diagnostic, prognostic and therapeutic implications in heart failure.

By Ruilope Urioste, Luis Miguel. European heart journal, 2016 . 37(33):2577-85. , Formato Vancouver: Van Veldhuisen DJ, Ruilope LM, Maisel AS, Damman K. Biomarkers of renal injury and function: diagnostic, prognostic and therapeutic implications in heart failure. Eur Heart J. 2016 Sep 1;37(33):2577-85.

Place Hold on Biomarkers of renal injury and function: diagnostic, prognostic and therapeutic implications in heart failure.

Utilidad de la espironolactona en el manejo farmacológico de la hipertensión arterial resistente. Comentarios sobre el estudio Pathway-2.

By Prado, José C | Ruilope Urioste, Luis Miguel | Segura de la Morena, Julián. Hipertensión y riesgo vascular, 2016 . 33(4):150-4. , Formato Vancouver: Prado JC, Ruilope LM, Segura J. Utilidad de la espironolactona en el manejo farmacológico de la hipertensión arterial resistente. Comentarios sobre el estudio Pathway-2. Hipertens Riesgo Vasc. 2016 Oct-Dec;33(4):150-4.

Place Hold on Utilidad de la espironolactona en el manejo farmacológico de la hipertensión arterial resistente. Comentarios sobre el estudio Pathway-2.

Association Between High and Very High Albuminuria and Nighttime Blood Pressure: Influence of Diabetes and Chronic Kidney Disease.

By Ruiz Hurtado, Gema | Ruilope Urioste, Luis Miguel | Segura de la Morena, Julián. Diabetes care, 2016 . 39(10):1729-37. , Formato Vancouver: Ruiz Hurtado G, Ruilope LM, de la Sierra A, Sarafidis P, de la Cruz JJ, Gorostidi M et al. Association Between High and Very High Albuminuria and Nighttime Blood Pressure: Influence of Diabetes and Chronic Kidney Disease. Diabetes Care. 2016 Oct;39(10):1729-37.

Place Hold on Association Between High and Very High Albuminuria and Nighttime Blood Pressure: Influence of Diabetes and Chronic Kidney Disease.

Ambulatory blood pressure in hypertensive patients with inclusion criteria for the SPRINT trial.

By Segura de la Morena, Julián | Ruilope Urioste, Luis Miguel. Journal of the American Society of Hypertension: JASH, 2016 . 10(12):947-953.e5. , Formato Vancouver: De la Sierra A, Banegas JR, Divisón JA, Gorostidi M, Vinyoles E, de la Cruz JJ et al. Ambulatory blood pressure in hypertensive patients with inclusion criteria for the SPRINT trial. J Am Soc Hypertens. 2016 Dec;10(12):947-953.e5.

Place Hold on Ambulatory blood pressure in hypertensive patients with inclusion criteria for the SPRINT trial.

Ambulatory blood pressure monitoring in daily clinical practice - the Spanish ABPM Registry experience.

By Ruilope Urioste, Luis Miguel | Segura de la Morena, Julián. European journal of clinical investigation, 2016 . 46(1):92-8. , Formato Vancouver: Gorostidi M, Banegas JR, de la Sierra A, Vinyoles E, Segura J, Ruilope LM. Ambulatory blood pressure monitoring in daily clinical practice - the Spanish ABPM Registry experience. Eur J Clin Invest. 2016 Jan;46(1):92-8.

Place Hold on Ambulatory blood pressure monitoring in daily clinical practice - the Spanish ABPM Registry experience.

Adherence to the "Mediterranean Diet" in Spain and Its Relationship with Cardiovascular Risk (DIMERICA Study).

By Guerrero, Lucía | Ramos, Elena | Ruilope Urioste, Luis Miguel. Nutrients, 2016 . 8(11):680. , Formato Vancouver: Abellán Alemán J, Zafrilla Rentero MP, Montoro García S, Mulero J, Pérez Garrido A, Leal M et al. Adherence to the "Mediterranean Diet" in Spain and Its Relationship with Cardiovascular Risk (DIMERICA Study). Nutrients. 2016 Oct 28;8(11):680.

Place Hold on Adherence to the "Mediterranean Diet" in Spain and Its Relationship with Cardiovascular Risk (DIMERICA Study).

Trends in hypertension control among the older population of Spain from 2000 to 2001 to 2008 to 2010: role of frequency and intensity of drug treatment.

By Ruilope Urioste, Luis Miguel. Circulation. Cardiovascular quality and outcomes, 2015 . 8(1):67-76. , Formato Vancouver: Banegas JR, Navarro Vidal B, Ruilope LM, de la Cruz JJ, López García E, Rodríguez Artalejo F et al. Trends in hypertension control among the older population of Spain from 2000 to 2001 to 2008 to 2010: role of frequency and intensity of drug treatment. Circ Cardiovasc Qual Outcomes. 2015 Jan;8(1):67-76.

Place Hold on Trends in hypertension control among the older population of Spain from 2000 to 2001 to 2008 to 2010: role of frequency and intensity of drug treatment.

Salutary cardiovascular effects of antidiabetic drugs: myth or fact?.

By Ruiz Hurtado, Gema | Ruilope Urioste, Luis Miguel. Journal of hypertension, 2015 . 33(11):2198-9. , Formato Vancouver: Ruiz Hurtado G, Ruilope LM. Salutary cardiovascular effects of antidiabetic drugs: myth or fact? J Hypertens. 2015 Nov;33(11):2198-9.

Place Hold on Salutary cardiovascular effects of antidiabetic drugs: myth or fact?.

Role of neprilysin inhibitor combinations in hypertension: insights from hypertension and heart failure trials.

By Ruilope Urioste, Luis Miguel. European heart journal, 2015 . 36(30):1967-73. , Formato Vancouver: Bavishi C, Messerli FH, Kadosh B, Ruilope LM, Kario K. Role of neprilysin inhibitor combinations in hypertension: insights from hypertension and heart failure trials. Eur Heart J. 2015 Aug 7;36(30):1967-73.

Place Hold on Role of neprilysin inhibitor combinations in hypertension: insights from hypertension and heart failure trials.

Proceedings from the European clinical consensus conference for renal denervation: considerations on future clinical trial design.

By Ruilope Urioste, Luis Miguel. European heart journal, 2015 . 36(33):2219-27. , Formato Vancouver: Mahfoud F, Böhm M, Azizi M, Pathak A, Durand Zaleski I, Ewen S et al. Proceedings from the European clinical consensus conference for renal denervation: considerations on future clinical trial design. Eur Heart J. 2015 Sep 1;36(33):2219-27.

Place Hold on Proceedings from the European clinical consensus conference for renal denervation: considerations on future clinical trial design.

Prediction of development and maintenance of high albuminuria during chronic renin-angiotensin suppression by plasma proteomics.

By Ruiz Hurtado, Gema | Segura de la Morena, Julián | Ruilope Urioste, Luis Miguel. International journal of cardiology, 2015 . 196:170-7. , Formato Vancouver: Baldán Martín M, de la Cuesta F, Alvárez Llamas G, González Calero L, Ruiz Hurtado G, Moreno Luna R et al. Prediction of development and maintenance of high albuminuria during chronic renin-angiotensin suppression by plasma proteomics. Int J Cardiol. 2015 Oct 1;196:170-7.

Place Hold on Prediction of development and maintenance of high albuminuria during chronic renin-angiotensin suppression by plasma proteomics.

New antihypertensive drugs under development.

By Ruilope Urioste, Luis Miguel. Current medicinal chemistry, 2015 . 22(3):305-42. , Formato Vancouver: Tamargo J, Duarte J, Ruilope LM. New antihypertensive drugs under development. Curr Med Chem. 2015;22(3):305-42.

Place Hold on New antihypertensive drugs under development.

LCZ696, The Need for an Indication in Arterial Hypertension.

By Prado, José C | Ruilope Urioste, Luis Miguel. American journal of hypertension, 2015 . 28(12):1403-4. , Formato Vancouver: Prado JC, Ruilope LM. LCZ696, The Need for an Indication in Arterial Hypertension. Am J Hypertens. 2015 Dec;28(12):1403-4.

Place Hold on LCZ696, The Need for an Indication in Arterial Hypertension.

First report of the Global SYMPLICITY Registry on the effect of renal artery denervation in patients with uncontrolled hypertension.

By Ruilope Urioste, Luis Miguel. Hypertension (Dallas, Tex.:1979), 2015 . 65(4):766-74. , Formato Vancouver: Böhm M, Mahfoud F, Ukena C, Hoppe UC, Narkiewicz K, Negoita M et al. First report of the Global SYMPLICITY Registry on the effect of renal artery denervation in patients with uncontrolled hypertension. Hypertension. 2015 Apr;65(4):766-74.

Place Hold on First report of the Global SYMPLICITY Registry on the effect of renal artery denervation in patients with uncontrolled hypertension.

Factors influencing return-to-work after cerebrovascular disease: the importance of previous cardiovascular risk.

By Ruilope Urioste, Luis Miguel. European journal of preventive cardiology, 2015 . 22(9):1220-7. , Formato Vancouver: Catalina Romero C, Ruilope LM, Sánchez Chaparro MA, Valdivielso P, Cabrera Sierra M, Fernández Labandera C et al. Factors influencing return-to-work after cerebrovascular disease: the importance of previous cardiovascular risk. Eur J Prev Cardiol. 2015 Sep;22(9):1220-7.

Place Hold on Factors influencing return-to-work after cerebrovascular disease: the importance of previous cardiovascular risk.

Ethnic differences in the degree of morning blood pressure surge and in its determinants between Japanese and European hypertensive subjects: data from the ARTEMIS study.

By Ruilope Urioste, Luis Miguel. Hypertension (Dallas, Tex. :1979), 2015 . 66(4):750-6. , Formato Vancouver: Hoshide S, Kario K, de la Sierra A, Bilo G, Schillaci G, Banegas JR et al. Ethnic differences in the degree of morning blood pressure surge and in its determinants between Japanese and European hypertensive subjects: data from the ARTEMIS study. Hypertension. 2015 Oct;66(4):750-6.

Place Hold on Ethnic differences in the degree of morning blood pressure surge and in its determinants between Japanese and European hypertensive subjects: data from the ARTEMIS study.

Erratum to: The fixed-dose combination of olmesartan/amlodipine was superior in central aortic blood pressure reduction compared with perindopril/amlodipine: a randomized, double-blind trial in patients with hypertension.

By Ruilope Urioste, Luis Miguel. Advances in therapy, 2015 . 32(2):184-5. , Formato Vancouver: Ruilope L, Schaefer A. Erratum to: The fixed-dose combination of olmesartan/amlodipine was superior in central aortic blood pressure reduction compared with perindopril/amlodipine: a randomized, double-blind trial in patients with hypertension. Adv Ther. 2015 Feb;32(2):184-5.

Place Hold on Erratum to: The fixed-dose combination of olmesartan/amlodipine was superior in central aortic blood pressure reduction compared with perindopril/amlodipine: a randomized, double-blind trial in patients with hypertension.

Effects of the dual peroxisome proliferator-activated receptor activator aleglitazar in patients with Type 2 Diabetes mellitus or prediabetes.

By Ruilope Urioste, Luis Miguel. American heart journal, 2015 . 170(1):117-22. , Formato Vancouver: Erdmann E, Califf R, Gerstein HC, Malmberg K, Ruilope L, Schwartz GG, Wedel H, Volz D, Ditmarsch M, Svensson A, Bengus M. Effects of the dual peroxisome proliferator-activated receptor activator aleglitazar in patients with Type 2 Diabetes mellitus or prediabetes. Am Heart J. 2015 Jul;170(1):117-22.

Place Hold on Effects of the dual peroxisome proliferator-activated receptor activator aleglitazar in patients with Type 2 Diabetes mellitus or prediabetes.

Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.

By Ruilope Urioste, Luis Miguel. JAMA, 2015 . 314(9):884-94. , Formato Vancouver: Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H et al; Mineralocorticoid Receptor Antagonist Tolerability Study–Diabetic Nephropathy (ARTS-DN) Study Group. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial. JAMA. 2015 Sep 1;314(9):884-94.

Place Hold on Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.

Estudio del riesgo cardiovascular en pacientes con bloqueo del sistema renina-angiotensina a través del proteoma de las vesículas extracelulares circulantes.

By Ruiz Hurtado, Gema | Segura de la Morena, Julián | Ruilope Urioste, Luis Miguel. Hipertensión y riesgo vascular, 2016 . 33(1):21-7. , Formato Vancouver: De la Cuesta F, Baldan Marín M, Mourino Alvárez L, Sastre Oliva T, Alvárez Llamas G, González Calero L et al. Estudio del riesgo cardiovascular en pacientes con bloqueo del sistema renina-angiotensina a través del proteoma de las vesículas extracelulares circulantes. Hipertens Riesgo Vasc. 2016 Jan-Mar;33(1):21-7.

Place Hold on Estudio del riesgo cardiovascular en pacientes con bloqueo del sistema renina-angiotensina a través del proteoma de las vesículas extracelulares circulantes.

Cardiorenal protection during chronic renin-angiotensin-aldosterone system suppression: evidences and caveats.

By Ruiz Hurtado, Gema | Ruilope Urioste, Luis Miguel. European heart journal. Cardiovascular pharmacotherapy, 2015 . 1(2):126-31. , Formato Vancouver: Ruiz Hurtado G, Ruilope LM. Cardiorenal protection during chronic renin-angiotensin-aldosterone system suppression: evidences and caveats. Eur Heart J Cardiovasc Pharmacother. 2015 Apr;1(2):126-31.

Place Hold on Cardiorenal protection during chronic renin-angiotensin-aldosterone system suppression: evidences and caveats.

An update of the blockade of the renin angiotensin aldosterone system in clinical practice.

By Ruiz Hurtado, Gema | Ruilope Urioste, Luis Miguel | Segura de la Morena, Julián. Expert opinion on pharmacotherapy, 2015 . 16(15):2283-92. , Formato Vancouver: Márquez DF, Ruiz-Hurtado G, Ruilope LM, Segura J. An update of the blockade of the renin angiotensin aldosterone system in clinical practice. Expert Opin Pharmacother. 2015;16(15):2283-92.

Place Hold on An update of the blockade of the renin angiotensin aldosterone system in clinical practice.

Ambulatory blood pressure monitoring in daily clinical practice - the Spanish ABPM Registry experience.

By Segura de la Morena, Julián | Ruilope Urioste, Luis Miguel. European journal of clinical investigation, 2016 . 46(1):92-8. , Formato Vancouver: Gorostidi M, Banegas JR, de la Sierra A, Vinyoles E, Segura J, Ruilope LM. Ambulatory blood pressure monitoring in daily clinical practice - the Spanish ABPM Registry experience. Eur J Clin Invest. 2016 Jan;46(1):92-8.

Place Hold on Ambulatory blood pressure monitoring in daily clinical practice - the Spanish ABPM Registry experience.

Ambulatory Blood Pressure Monitoring in the Diagnosis, Prognosis, and Management of Resistant Hypertension: Still a Matter of our Resistance?.

By Ruilope Urioste, Luis Miguel. Current hypertension reports, 2015 . 17(10):78. , Formato Vancouver: Lazaridis AA, Sarafidis PA, Ruilope LM. Ambulatory Blood Pressure Monitoring in the Diagnosis, Prognosis, and Management of Resistant Hypertension: Still a Matter of our Resistance? Curr Hypertens Rep. 2015 Oct;17(10):78.

Place Hold on Ambulatory Blood Pressure Monitoring in the Diagnosis, Prognosis, and Management of Resistant Hypertension: Still a Matter of our Resistance?.

Ambulatory Blood Pressures in Hypertensive Patients Treated With One Antihypertensive Agent: Differences Among Drug Classes and Among Drugs Belonging to the Same Class.

By Segura de la Morena, Julián | Ruilope Urioste, Luis Miguel. The journal of clinical hypertension, 2015 . 17(11):857-65. , Formato Vancouver: De la Sierra A, Gorostidi M, Banegas JR, Segura J, Vinyoles E, de la Cruz JJ et al. Ambulatory Blood Pressures in Hypertensive Patients Treated With One Antihypertensive Agent: Differences Among Drug Classes and Among Drugs Belonging to the Same Class. J Clin Hypertens (Greenwich). 2015 Nov;17(11):857-65.

Place Hold on Ambulatory Blood Pressures in Hypertensive Patients Treated With One Antihypertensive Agent: Differences Among Drug Classes and Among Drugs Belonging to the Same Class.

Ambulatory and home blood pressure monitoring in people with chronic kidney disease. Time to abandon clinic blood pressure measurements?.

By Ruiz Hurtado, Gema | Ruilope Urioste, Luis Miguel. Current opinion in nephrology and hypertension, 2015 . 24(6):488-91. , Formato Vancouver: Ruiz Hurtado G, Gorostidi M, Waeber B, Ruilope LM. Ambulatory and home blood pressure monitoring in people with chronic kidney disease. Time to abandon clinic blood pressure measurements?. Curr Opin Nephrol Hypertens. 2015 Nov;24(6):488-91.

Place Hold on Ambulatory and home blood pressure monitoring in people with chronic kidney disease. Time to abandon clinic blood pressure measurements?.

Aldosterone antagonists and renal denervation: friends or foes?

By Ruilope Urioste, Luis Miguel. Hypertension, 2015 . 65(2):280-2. , Formato Vancouver: Mahfoud F, Ruilope LM, Böhm M, Schmieder RE. Aldosterone antagonists and renal denervation: friends or foes?. Hypertension. 2015 Feb;65(2):280-2.

Place Hold on Aldosterone antagonists and renal denervation: friends or foes?

Was there real denervation in the SYMPLICITY HTN-3 trial?.

By Ruilope Urioste, Luis Miguel. European heart journal, 2014 . 35(26):1699-1700. , Formato Vancouver: Ruilope LM. Was there real denervation in the SYMPLICITY HTN-3 trial? Eur Heart J. 2014 Jul;35(26):1699-1700.

Place Hold on Was there real denervation in the SYMPLICITY HTN-3 trial?.

Usefulness of ambulatory blood pressure monitoring (ABPM) in daily clinical practice: Data from the Spanish ABPM registry.

By Segura de la Morena, Julián | Ruilope Urioste, Luis Miguel. Clinical and experimental pharmacology & physiology, 2014 . 41(1):30-6. , Formato Vancouver: Segura J, Banegas JR, Ruilope LM. Usefulness of ambulatory blood pressure monitoring (ABPM) in daily clinical practice: Data from the Spanish ABPM registry. Clin Exp Pharmacol Physiol. 2014 Jan;41(1):30-6.

Place Hold on Usefulness of ambulatory blood pressure monitoring (ABPM) in daily clinical practice: Data from the Spanish ABPM registry.

Understanding visit-to-visit blood pressure variability.

By Ruilope Urioste, Luis Miguel. Journal of clinical hypertension (Greenwich, Conn.), 2014 . 16(1):8-9. , Formato Vancouver: Ruilope LM. Understanding visit-to-visit blood pressure variability. J Clin Hypertens (Greenwich). 2014 Jan;16(1):8-9.

Place Hold on Understanding visit-to-visit blood pressure variability.

The Randomized Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) observational follow-up study: benefits of RAS blockade with olmesartan treatment are sustained after study discontinuation.

By Ruilope Urioste, Luis Miguel. Journal of the American Heart Association, 2014 . 3(2):e000810. , Formato Vancouver: Menne J, Ritz E, Ruilope LM, Chatzikyrkou C, Viberti G, Haller H. The Randomized Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) observational follow-up study: benefits of RAS blockade with olmesartan treatment are sustained after study discontinuation. J Am Heart Assoc. 2014;3(2):e000810.

Place Hold on The Randomized Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) observational follow-up study: benefits of RAS blockade with olmesartan treatment are sustained after study discontinuation.

Resistant hypertension and renal denervation. Considerations on the results of the SYMPLICITY HTN-3 trial.

By Ruilope Urioste, Luis Miguel | Arribas Ynsaurriaga, Fernando . Revista española de cardiología (English ed.) 2014 . 67(11):881-2. , Formato Vancouver: Ruilope LM, Arribas F. Resistant hypertension and renal denervation. Considerations on the results of the SYMPLICITY HTN-3 trial. Rev Esp Cardiol (Engl Ed). 2014 Nov;67(11):881-2.

Place Hold on Resistant hypertension and renal denervation. Considerations on the results of the SYMPLICITY HTN-3 trial.

Renin-angiotensin system blockade: time for a reappraisal?.

By Ruilope Urioste, Luis Miguel. European heart journal, 2014 . 35(26):1703-5. , Formato Vancouver: Ruilope LM. Renin-angiotensin system blockade: time for a reappraisal? Eur Heart J. 2014 Jul;35(26):1703-5.

Place Hold on Renin-angiotensin system blockade: time for a reappraisal?.

Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy.

By Ruilope Urioste, Luis Miguel. American journal of nephrology, 2014 . 40(6):572-81. , Formato Vancouver: Ruilope LM, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H et al. Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy. Am J Nephrol. 2014;40(6):572-81.

Place Hold on Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy.

Prevention of electrocardiographic left ventricular remodeling by the angiotensin receptor blocker olmesartan in patients with type 2 diabetes.

By Ruilope Urioste, Luis Miguel. Journal of hypertension, 2014 . 32(11):2267-76; discussion 2276. , Formato Vancouver: Raff U, Ott C, Ruilope LM, Menne J, Haller H, Schmieder RE. Prevention of electrocardiographic left ventricular remodeling by the angiotensin receptor blocker olmesartan in patients with type 2 diabetes. J Hypertens. 2014 Nov;32(11):2267-76; discussion 2276.

Place Hold on Prevention of electrocardiographic left ventricular remodeling by the angiotensin receptor blocker olmesartan in patients with type 2 diabetes.

Prevención de la enfermedad cardiovascular. Actuación terapéutica actual en atención primaria. Estudio Prevencat

By Ruilope Urioste, Luis Miguel. Revista Española de Cardiología, 2003 . 2003;56(Supl. 2):25-26 , Formato Vancouver: Barrios Alonso V, Ruilope LM, Llisterri JL, Álvarez-Sala Morís JL, Esmatjes E, Franch J, et al. Prevención de la enfermedad cardiovascular. Actuación terapéutica actual en atención primaria. Estudio Prevencat. Rev Esp Cardiol. 2003;56(Supl. 2):25-26

Place Hold on Prevención de la enfermedad cardiovascular. Actuación terapéutica actual en atención primaria. Estudio Prevencat

P271. ¿Es adecuada la definición actual de glucosa anómala en ayunas en pacientes hipertensos?

By Segura de la Morena, Julián | Ruilope Urioste, Luis Miguel. Revista Española de Cardiología, 2003 . 2003;56(Supl 2):56 , Formato Vancouver: Roldán Suárez C, Tomás JP, Campos C, Segura J, Barrios Alonso V, Ruilope LM, et al. P271. ¿Es adecuada la definición actual de glucosa anómala en ayunas en pacientes hipertensos? Rev Esp Cardiol. 2003;56(Supl 2):56

Place Hold on P271. ¿Es adecuada la definición actual de glucosa anómala en ayunas en pacientes hipertensos?

Una nueva guía de la Organización Mundial de la Salud y la Sociedad Internacional de Hipertensión para el manejo de la hipertensión arterial: hacia la guía común

By Ruilope Urioste, Luis Miguel. Revista Española de Cardiología, 1999 . 1999;52(6):381-382 , Formato Vancouver: Suárez C, Ruilope LM. Una nueva guía de la Organización Mundial de la Salud y la Sociedad Internacional de Hipertensión para el manejo de la hipertensión arterial: hacia la guía común. Rev Esp Cardiol. 1999 Jun;52(6):381-2

Place Hold on Una nueva guía de la Organización Mundial de la Salud y la Sociedad Internacional de Hipertensión para el manejo de la hipertensión arterial: hacia la guía común

One step forward for serelaxin as a promising therapy in cardiac fibrosis.

By Ruilope Urioste, Luis Miguel. Hypertension (Dallas, Tex. : 1979), 2014 . 64(2):229-30. , Formato Vancouver: Fernández Alfonso MS, Ruilope LM. One step forward for serelaxin as a promising therapy in cardiac fibrosis. Hypertension. 2014 Aug;64(2):229-30.

Place Hold on One step forward for serelaxin as a promising therapy in cardiac fibrosis.

Nocturnal hypertension or nondipping: which is better associated with the cardiovascular risk profile?.

By Segura de la Morena, Julián | Ruilope Urioste, Luis Miguel. American journal of hypertension, 2014 . 27(5):680-7. , Formato Vancouver: De la Sierra A, Gorostidi M, Banegas JR, Segura J, de la Cruz JJ, Ruilope LM. Nocturnal hypertension or nondipping: which is better associated with the cardiovascular risk profile?. Am J Hypertens. 2014 May;27(5):680-7.

Place Hold on Nocturnal hypertension or nondipping: which is better associated with the cardiovascular risk profile?.

Night-time heart rate cut-off point definition by resting office tachycardia in untreated hypertensive patients: data of the Spanish ABPM registry.

By Segura de la Morena, Julián | Ruilope Urioste, Luis Miguel. Journal of hypertension, 2014 . 32(5):1016-24. , Formato Vancouver: Vinyoles E, de la Sierra A, Roso A, de la Cruz JJ, Gorostidi M, Segura J et al; Spanish ABPM Registry investigators. Night-time heart rate cut-off point definition by resting office tachycardia in untreated hypertensive patients: data of the Spanish ABPM registry. J Hypertens. 2014 May;32(5):1016-24.

Place Hold on Night-time heart rate cut-off point definition by resting office tachycardia in untreated hypertensive patients: data of the Spanish ABPM registry.

Long-term blockade of the renin-angiotensin system: an adequate evaluation is still needed.

By Segura de la Morena, Julián | Ruilope Urioste, Luis Miguel. Hypertension research : official journal of the Japanese Society of Hypertension, 2014 . 37(8):701-2. , Formato Vancouver: Segura J, Ruilope LM. Long-term blockade of the renin-angiotensin system: an adequate evaluation is still needed. Hypertens Res. 2014 Aug;37(8):701-2.

Place Hold on Long-term blockade of the renin-angiotensin system: an adequate evaluation is still needed.

The authors reply

By Ruilope Urioste, Luis Miguel. Kidney international, 2014 . 86(4):855. , Formato Vancouver: Sarafidis PA, Ruilope LM. The authors reply. Kidney Int. 2014 Oct;86(4):855. [Lower blood pressure target in nondiabetic proteinuric chronic kidney disease is not justified. Kidney Int. 2014;86(4):855]

Place Hold on The authors reply

Influence of high cardiovascular risk in asymptomatic people on the duration and cost of sick leave: results of the ICARIA study.

By Ruilope Urioste, Luis Miguel | Cerezo Olmos, César. European heart journal, 2014 . 35(5):299-306. , Formato Vancouver: Calvo-Bonacho E, Ruilope LM, Sánchez-Chaparro MA, Cerezo C, Catalina-Romero C, Martínez-Muñoz P et al. A. Influence of high cardiovascular risk in asymptomatic people on the duration and cost of sick leave: results of the ICARIA study. Eur Heart J. 2014 Feb;35(5):299-306.

Place Hold on Influence of high cardiovascular risk in asymptomatic people on the duration and cost of sick leave: results of the ICARIA study.

Heart rate and heart rate variability in resistant versus controlled hypertension and in true versus white-coat resistance.

By Ruilope Urioste, Luis Miguel | Segura de la Morena, Julián. Journal of human hypertension, 2014 . 28(7):416-20. , Formato Vancouver: De la Sierra A, Calhoun DA, Vinyoles E, Banegas JR, De la Cruz JJ, Gorostidi M et al. Heart rate and heart rate variability in resistant versus controlled hypertension and in true versus white-coat resistance. J Hum Hypertens. 2014 Jul;28(7):416-20.

Place Hold on Heart rate and heart rate variability in resistant versus controlled hypertension and in true versus white-coat resistance.

Estimating the glomerular filtration rate in the Spanish working population: chronic kidney disease prevalence and its association with risk factors.

By Ruilope Urioste, Luis Miguel. Journal of hypertension, 2014 . 32(10):1970-8. , Formato Vancouver: Sánchez-Chaparro MA, Calvo-Bonacho E, González-Quintela A, Cabrera M, Quevedo-Aguado L, Fernández-Labandera C et al; ICARIA (Ibermutuamur CArdiovascular RIsk Assessment) Study Group. Estimating the glomerular filtration rate in the Spanish working population: chronic kidney disease prevalence and its association with risk factors. J Hypertens. 2014 Oct;32(10):1970-8.

Place Hold on Estimating the glomerular filtration rate in the Spanish working population: chronic kidney disease prevalence and its association with risk factors.

Effects of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study.

By Ruilope Urioste, Luis Miguel. BMC nephrology, 2014 . 15:180. , Formato Vancouver: Ruilope L, Hanefeld M, Lincoff AM, Viberti G, Meyer-Reigner S, Mudie N et al. Effects of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study. BMC Nephrol. 2014 Nov 18;15:180.

Place Hold on Effects of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study.